Trial Profile
Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 26 Sep 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 20 Jul 2021 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.